.Sanofi is still set on taking its own multiple sclerosis (MS) med tolebrutinib to the FDA, execs have actually informed Intense Biotech, even with the
Read moreSanofi’s $80M bet on Key dystrophy medicine finishes in stage 3 go bust
.Merely four months after Sanofi wager $80 million in beforehand cash money on Fulcrum Therapeutics’ losmapimod, the system has ended in a phase 3 failure.The
Read moreSanofi picks brand-new CSO coming from in-stealth biotech
.After a couple of years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma crease, occupying the leading science area at Sanofi.Quigley will
Read moreSanofi pays out $110M upfront for late-stage radioligand therapy
.Sanofi has actually brought in an overdue access to the radioligand party, paying one hundred million europeans ($ 110 million) beforehand for international civil liberties
Read moreSanofi flunks MS study, inflicting yet another impact to Denali contract
.Sanofi has quit a phase 2 difficulty of Denali Therapeutics-partnered oditrasertib in several sclerosis. The French drugmaker tore the RIPK1 prevention ordeal from its own
Read moreSangamo slashes opportunity to market for Fabry genetics therapy as FDA agrees to accelerated permission bundle
.Sangamo Rehabs has pinpointed a faster way to market for its Fabry condition prospect, aligning with the FDA on a pathway that could slash three
Read moreSage lays off half of R&D crew and also shakes up C-suite once more
.Sage Therapies’ most current attempt to diminish its own pipe and also labor force will certainly see a 3rd of the biotech’s workers going to
Read moreRoivant introduces brand-new ‘vant’ to advance Bayer hypertension med
.Matt Gline is back along with a new ‘vant’ company, after the Roivant Sciences CEO spent Bayer $14 million beforehand for the civil liberties to
Read moreRoche is actually supporting out hopes that its injectable being overweight prospect could at some point display 25% weight management in late-stage test
.Roche is keeping out chances that its injectable weight problems possibility could ultimately illustrate 25% fat loss in late-stage trials, the pharma’s head of metabolic
Read moreRoche discards $120M tau possibility, coming back liberties to UCB
.Roche has given back the civil liberties to UCB’s anti-tau antibody bepranemab, leaving a $120 thousand bet on the Alzheimer’s illness drug applicant on the
Read more